Recent Quotes (30 days)

You have no recent quotes
chg | %

Kane Biotech Inc  

(Public, CVE:KNE)   Watch this stock  
Find more results for kne
0.0350
-0.0050 (-12.50%)
Jun 24 - Close
CVE data delayed by 15 mins - Disclaimer
Currency in CAD
Range 0.04 - 0.04
52 week 0.03 - 0.08
Open 0.04
Vol / Avg. 379,000.00/209,135.00
Mkt cap 5.78M
P/E     -
Div/yield     -
EPS -0.02
Shares 123.79M
Beta 0.71
Inst. own     -

Key stats and ratios

Q1 (Mar '16) 2015
Net profit margin -1570.39% -1634.49%
Operating margin -1429.77% -1541.18%
EBITD margin - -1500.50%
Return on average assets -179.78% -108.14%
Return on average equity -612.14% -189.46%
CDP Score - -

Address

162 - 196 Innovation Drive
WINNIPEG, MB R3T 2N2
Canada
+1-204-4531301 (Phone)
+1-204-8180374 (Fax)

Website links

Description

Kane Biotech Inc. is a Canada-based biotechnology company. The Company is engaged in the development and commercialization of products that prevent and remove microbial biofilms. The Company's technologies include DispersinB, AloSera, Aledex, Strix NB, bluestem and KBI Disinfectant. It is focused on the companion animal market with Strix NB brand for the veterinary segment and bluestem brand for the pet over the counter (OTC) retail market. The Company markets its oral care technology into the Canadian pet specialty market under the bluestem brand. It has over 100 pet specialty stores in Canada, which are engaged in selling the bluestem oral health products. It has various formulations in development, including formulations with antibiotics and the antibiofilm enzyme beta-N-Acetylglucosaminidase and antibiofilm-antimicrobial formulations for both the veterinary and human markets. It is focused on the development of oral care spray formulation and a water additive powder formulation.

Officers and directors

Philip Renaud Independent Chairman of the Board
Mark William Ahrens-Townsend President, Chief Executive Officer
Audrey Goertzen CPA Chief Financial Officer
Arvind K. Joshi M.D. Independent Director
Mark H. Nawacki Independent Director
Sarah Prichard Independent Director